<?xml version='1.0' encoding='utf-8'?>
<document id="30810774"><sentence text="Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38."><entity charOffset="0-9" id="DDI-PubMed.30810774.s1.e0" text="Pazopanib" /><entity charOffset="25-35" id="DDI-PubMed.30810774.s1.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.30810774.s1.e0" e2="DDI-PubMed.30810774.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30810774.s1.e0" e2="DDI-PubMed.30810774.s1.e1" /></sentence><sentence text="Pazopanib is an orally active, multi-targeted tyrosine kinase inhibitor"><entity charOffset="0-9" id="DDI-PubMed.30810774.s2.e0" text="Pazopanib" /><entity charOffset="46-54" id="DDI-PubMed.30810774.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.30810774.s2.e0" e2="DDI-PubMed.30810774.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30810774.s2.e0" e2="DDI-PubMed.30810774.s2.e1" /></sentence><sentence text=" A previous phase I study demonstrated that coadministration of pazopanib with irinotecan increases the area under the plasma concentration-time curve (AUC) for SN-38, an active metabolite of irinotecan"><entity charOffset="64-73" id="DDI-PubMed.30810774.s3.e0" text="pazopanib" /><entity charOffset="79-89" id="DDI-PubMed.30810774.s3.e1" text="irinotecan" /><entity charOffset="192-202" id="DDI-PubMed.30810774.s3.e2" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.30810774.s3.e0" e2="DDI-PubMed.30810774.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30810774.s3.e0" e2="DDI-PubMed.30810774.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30810774.s3.e0" e2="DDI-PubMed.30810774.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30810774.s3.e1" e2="DDI-PubMed.30810774.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30810774.s3.e1" e2="DDI-PubMed.30810774.s3.e2" /></sentence><sentence text=" To clarify the possible mechanism underlying that drug-drug interaction, we investigated the potential for pazopanib to inhibit UDP-glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which are involved in detoxification and hepatic uptake of SN-38, respectively"><entity charOffset="108-117" id="DDI-PubMed.30810774.s4.e0" text="pazopanib" /></sentence><sentence text="" /><sentence text="Human liver microsomes (HLMs) and recombinant human UGT1A1, and HEK293 cells stably transfected with OATP1B1 were used to evaluate the inhibitory effects of pazopanib against glucuronidation, and hepatic uptake of SN-38, respectively"><entity charOffset="157-166" id="DDI-PubMed.30810774.s6.e0" text="pazopanib" /></sentence><sentence text=" Kinetic analysis was performed to estimate inhibition constants, which were corrected for non-specific binding to enzyme sources (Ki,u values)" /><sentence text="" /><sentence text="Concentration-dependent inhibition of SN-38 glucuronidation was observed in the HLMs and recombinant human UGT1A1 experiments: Pazopanib noncompetitively inhibited SN-38 glucuronidation by HLMs (Ki,u = 1"><entity charOffset="127-136" id="DDI-PubMed.30810774.s9.e0" text="Pazopanib" /></sentence><sentence text="6 ± 0" /><sentence text="05 µM) and recombinant human UGT1A1 (Ki,u = 0" /><sentence text="69 ± 0" /><sentence text="02 µM)" /><sentence text=" Pazopanib-induced increases in SN-38 AUC estimated using Ki,u values were comparable to those observed in patients of the phase I study who received both irinotecan and pazopanib"><entity charOffset="1-10" id="DDI-PubMed.30810774.s14.e0" text="Pazopanib" /><entity charOffset="155-165" id="DDI-PubMed.30810774.s14.e1" text="irinotecan" /><entity charOffset="170-179" id="DDI-PubMed.30810774.s14.e2" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.30810774.s14.e0" e2="DDI-PubMed.30810774.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30810774.s14.e0" e2="DDI-PubMed.30810774.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30810774.s14.e0" e2="DDI-PubMed.30810774.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30810774.s14.e1" e2="DDI-PubMed.30810774.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30810774.s14.e1" e2="DDI-PubMed.30810774.s14.e2" /></sentence><sentence text=" Such results suggest that the drug-drug interaction is at least partially mediated by inhibition of UGT1A1" /><sentence text=" In contrast, pazopanib did not inhibit OATP1B1-mediated SN-38 uptake at concentrations up to 60 µM"><entity charOffset="14-23" id="DDI-PubMed.30810774.s16.e0" text="pazopanib" /></sentence><sentence text="" /><sentence text="Results showed that pazopanib inhibits UGT1A1-mediated SN-38 glucuronidation, but not OATP1B1-mediated SN-38 uptake"><entity charOffset="20-29" id="DDI-PubMed.30810774.s18.e0" text="pazopanib" /></sentence><sentence text="" /></document>